NCT01424540View on ClinicalTrials.gov

Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

September 1, 2011

Primary Completion Date

October 3, 2011

Study Completion Date

October 3, 2011

Conditions

Hepatitis C

Interventions

DRUG

GSK2336805 150mg

Single Dose

OTHER

Placebo

Single Dose

Trial Locations (1)

14202

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY